Cancer Immunotherapy Market – Global Market Size, Strategic Growth Drivers, Risk Assessment Framework, Regulatory Landscape Review, Competitive Intensity Mapping & Long-Term Industry Outlook to 2034
Overview
Cancer Immunotherapy Market size was valued at USD 140.34 Bn. in 2025. Monoclonal Antibodies, one of the segments reviewed in our reports dominated the Cancer Immunotherapy Market.
Cancer Immunotherapy Market Overview:
Cancer immunotherapy is a treatment that uses the body's immune system to fight cancer. Cancer cells have the ability to invade the immune system through a variety of mechanisms. Immunotherapy focuses on these mechanisms and develops another mechanism to restore the immune system and its ability to destroy cancer cells. Cancer immunotherapy is a cancer treatment that strengthens the immune system's ability to fight cancer. This treatment is preferred over older techniques because it provides long-term protection against cancer, has fewer side effects, and treats a wider range of cancers.
Cancer Immunotherapy Market Snapshot
To know about the Research Methodology :- Request Free Sample Report
Cancer Immunotherapy Market Dynamics:
Chemotherapy and radiation therapy are most commonly used to treat cancer in current scenarios. However, the side effects associated with these treatments are of paramount concern to healthcare professionals and patients. Drugs like Keytruda and Opdivo induce the immune system to destroy carcinogenic cells. Immunotherapy helps to act on target cells that only selectively attack cancer cells because they cannot be captured by chemotherapeutic agents. Due to this mechanism, products such as monoclonal antibodies, checkpoint inhibitors, and cell therapies are becoming popular for better and more effective therapeutic effects. This increase in the adoption of immunotherapy is driving market growth.
The development of various bioinformatics tools such as the Basic Local Alignment Search Tool and the European Molecular Biology Open Software Suite will help researchers select the right molecule for drug design. The introduction of these tools has significantly reduced the cost and time frame of the drug development process. Using bioinformatics tools as a strategy is one of the most important and useful approaches to developing clinical medicine for clinical research and application and improving outcomes for cancer patients. These tools also help identify the post-mutation function of proteins and increase their chances of successful drug development. This technology has fueled interest from pharmaceutical, biotechnology companies, and research organizations in increasing the uptake of cancer immunotherapy research projects. These factors are expected to drive the cancer immunotherapy market through the forecast period.
The increasing number of cancer patients over the globe is driving the demand for cancer immunotherapy. According to MMR Report, Lung Cancer is one of the most common types of cancer in the world. The number of lungs patient reached 2.4 million in 2022. Cancer incidence has increased in developing countries (the Asia Pacific and Africa) and now accounts for approximately 55 % of cases and 66% of cancer deaths worldwide. An increase in the number of cancer patients is leading to the acceptance of cancer immunotherapy rapidly. Increasing survival in patients who are taking cancer immunotherapy as a treatment option is expected to drive the growth of the market through the forecast period.
Cancer immunotherapy is shown to play an important role in maintaining the immune system and targeting infectious pathogens that can cause cancer through the production of antibodies. Cancer immunotherapy is considered a new treatment and given the enormous burden of cancer cases and the side effects of current therapies, the market is expected to grow rapidly through the forecast period.
The presence of immunotherapeutic agents such as Keytruda has succeeded in increasing the life expectancy of some mesothelioma patients in clinical trials that are expected to have a positive impact on the market. With fewer side effects compared to traditional chemotherapy and improved efficacy and accuracy of new therapies. These factors are driving the demand for cancer immunotherapy in the market.
Various types of cancer, such as melanoma, show resistance to chemotherapy and radiation therapy, the cost of cancer treatment, and limited information and fierce competition in the product development cycle are restraining the market demand. Depending on the type of cancer or cancer patient, the development of high-quality new drugs can be very complex and limit market demand. Lack of expertise and people's awareness can hinder the market growth.
Cancer Immunotherapy Market Segment Analysis:
By Technology, Monoclonal Antibodies dominated the market with a 42 % share in 2025. They have the capability to restore, enhance and mimic the immune system's response and are majorly defensive on the cancer cells. They are used to treat a variety of cancers like breast cancer, lymphoma, lung cancer, brain cancer, etc. They are designed to identify and create a targeted immune response to cancer cells based on their proteins on the cell surface and fogo normal cells.
Cytokines are expected to grow at a CAGR of 5 % through the forecast period. They are tiny proteins that play an important role in regulating the growth and activity of the immune system and blood cells. When they're released, they tell the immune system to get to work. All blood cells and other cells that aid the body's immunological and inflammatory responses are affected by cytokines. They also aid anti-cancer activities by transmitting signals that cause aberrant cells to perish while normal cells live longer. These factors are expected to drive the market growth through the forecast period.
By Application, Lung Cancer dominated the market with 44 % in 2025. The introduction of harmful products such as E-cigarettes is increasing cancer patients. Lung cancer is the highest affecting cancer worldwide and rising awareness programs for therapy. These factors are driving the growth of the segment in the market.
The melanoma segment is expected to grow at a CAGR of 6% through the forecast period. Growing focus on patient safety, increasing the 5-year survival rate of the patients, high adoption of this therapy. Recognizing the potential of immunotherapy in multiple myeloma, major players in the immunotherapy market such as Celgene, Amgen, Janssen, and Juno Therapeutics engaged in multiple collaborations to evaluate certain drug entities for the treatment of melanoma. These factors are expected to drive the growth of the segment in the market.
By End Use, the Hospital Segment dominated the market with a 60 % share in 2025. Extensive use of cancer immunotherapy in the hospitals and higher preference toward hospitals are the factors driving the market growth of the segment.
Cancer Research Center is expected to grow at a CAGR of 4 % through the forecast period. Increasing research and development and government investment are factors expected to drive the growth of the segment through the forecast period.
Cancer Immunotherapy Market Regional Insights:
North America dominated the market with a 45 % share in 2025. Increasing cancer patients, rising accessibility to modern therapy, and growing geriatric population are driving the demand for cancer immunotherapy in the region. The region has the highest cancer-caused population, increasing biotechnology companies and technological advancements such as CRISPR in cancer treatments. These factors are driving the market growth of cancer immunotherapy in the region.
Asia Pacific is expected to grow at a CAGR of 7 % through the forecast period. The cancers with a high level of mutations include melanoma, lung, bladder, stomach and oesophageal cancer are highly prevalent in this region. The large number of patients seeking treatment with low cost, increasing government spending on healthcare, key players' huge investments, etc. are the factors expected to drive the market growth in this region through the forecast period.
The objective of the report is to present a comprehensive analysis of the Cancer Immunotherapy market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.
PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding the Cancer Immunotherapy market dynamics, structure by analyzing the market segments and projecting the Cancer Immunotherapy market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Cancer Immunotherapy market make the report investor’s guide.
Cancer Immunotherapy Market Recent Industry Developments:
| Date | Company | Development | Impact |
|---|---|---|---|
| 21 October 2025 | Nxera Pharma | Nxera Pharma and partner Cancer Research UK successfully completed a Phase 1 clinical trial of the oral EP4 antagonist HTL0039732 in combination with atezolizumab. | The treatment demonstrated encouraging early efficacy and tumor reduction in immunotherapy-resistant solid tumors, clearing the path to launch a Phase 2a expansion trial. |
| 26 January 2026 | Amgen | The U.S. Food and Drug Administration published its official approval summary for Amgen’s bispecific T-cell engager tarlatamab. | The commercial approval expands targeted immunotherapy access for adult patients suffering from extensive-stage small cell lung cancer (ES-SCLC). |
| 12 February 2026 | AstraZeneca | The U.S. Food and Drug Administration finalized its clinical review and regulatory approval summary for AstraZeneca’s checkpoint inhibitor durvalumab (Imfinzi). | The regulatory milestone solidifies its clinical footprint for the treatment of adult patients diagnosed with muscle-invasive bladder cancer (MIBC). |
| 06 May 2026 | Diakonos Oncology | Diakonos Oncology was granted FDA Fast Track designation for its unique patient-derived dendritic cell therapy, DOC1021 (dubodencel). | The designation expedites clinical development and review timelines to treat patients with unresectable or metastatic cutaneous melanoma. |
| 11 May 2026 | Poolbeg Pharma | Poolbeg Pharma secured formal notification of a Canadian patent grant for its lead asset POLB 001. | The patent expands global intellectual property protections specifically for the prevention of severe cancer immunotherapy-induced cytokine release syndrome (CRS). |
Cancer Immunotherapy Market Scope: Inquire before buying
| Cancer Immunotherapy Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 140.34 USD Billion |
| Forecast Period 2026-2034 CAGR: | 9% | Market Size in 2034: | 304.8 USD Billion |
| Segments Covered: | by Therapy Type | Monoclonal Antibodies Naked Monoclonal Antibodies Conjugated Monoclonal Antibodies Bispecific Monoclonal Antibodies Immune Checkpoint Inhibitors PD-1 Inhibitors PD-L1 Inhibitors CTLA-4 Inhibitors Others (LAG-3, TIGIT, TIM-3, etc.) Cancer Vaccines Prophylactic Vaccines Therapeutic Vaccines Cell Therapies CAR-T Cell Therapy TCR-T Cell Therapy Dendritic Cell Therapy NK Cell Therapy Immunomodulators Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Interferons Interleukins Oncolytic Virus Therapy Others |
|
| by Route of Administration | Intravenous (IV) Subcutaneous (SC) Intramuscular (IM) Oral |
||
| by Distribution Channel | Hospital Pharmacies Retail Pharmacies Online Pharmacies Others |
||
| by Application | Lung Cancer Breast Cancer Colorectal Cancer Melanoma Prostate Cancer Head and Neck Cancer Ovarian Cancer Pancreatic Cancer Others |
||
Cancer Immunotherapy Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Cancer Immunotherapy Market Key Players are:
1. Merck & Co., Inc. (MSD)
2. Bristol Myers Squibb (BMS)
3. F. Hoffmann-La Roche Ltd.
4. AstraZeneca PLC
5. Novartis AG
6. Gilead Sciences, Inc. (Kite Pharma)
7. Johnson & Johnson (Janssen Biotech)
8. Pfizer Inc.
9. Eli Lilly and Company
10. Amgen Inc.
11. Regeneron Pharmaceuticals, Inc.
12. BioNTech SE
13. Moderna, Inc.
14. BeiGene Ltd.
15. Genmab A/S
16. Adaptimmune Therapeutics plc
17. Iovance Biotherapeutics, Inc.
18. Legend Biotech Corporation
19. Immunocore Holdings plc
20. Cellectis S.A.
21. Cartesian Therapeutics, Inc.
22. Allogene Therapeutics, Inc.
23. Arcellx, Inc.
24. Fate Therapeutics, Inc.
25. CRISPR Therapeutics AG
26. Nkarta, Inc.
27. Caribou Biosciences, Inc.
28. Sana Biotechnology, Inc.
29. TCR² Therapeutics Inc.
30. BioAtla, Inc.
31. Xencor, Inc.
32. Incyte Corporation
33. Coherus BioSciences, Inc.
34. Nektar Therapeutics
35. ImmunityBio, Inc.
36. Others
Frequently Asked Questions:
1] What segments are covered in the Cancer Immunotherapy Market report?
Ans. The segments covered in the Cancer Immunotherapy Market report are based on Technology, Application, and End-Use.
2] Which region is expected to hold the highest share in the Cancer Immunotherapy Market?
Ans. North America Region is expected to hold the highest share in the Cancer Immunotherapy Market.
3] What is the market size of the Cancer Immunotherapy Market by 2034?
Ans. The market size of the Cancer Immunotherapy Market by 2034 is USD 304.8 Bn.
4] Who are the top key players in the Cancer Immunotherapy Market?
Ans. Merck, Bayer AG, ELI Lilly and Company, Novartis, Pfizer, Janssen Global Service, Jhonson and Jhonson, Amgen, AstraZeneca, Hoffmann-La Roche Ltd., Bristol-Mayers Squibb, Squibb Company, Sun Pharmaceutical Industries Ltd, Fresenius Kabi AG, Dr. Reddy’s Laboratories Ltd., Bausch Health, LUPIN, Teva Pharmaceutical Industries Ltd, Mylan N.V., Hikma Pharmaceutical Plc., Apotex Inc., Immunomedics Inc., Amneal Pharmaceutical Inc., Aspen Holdings.
5] What was the market size of the Cancer Immunotherapy Market in 2025?
Ans. The market size of the Cancer Immunotherapy Market in 2025 was USD 140.34 Bn.